Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

Imatinib is a first-line tyrosine kinase inhibitor which is used in the management of chronic myeloid leukaemia. It will be used by all the patients in the 3 arms of the study (Groups A, B and C)

Artesunate has been established to reverse resistance to some chemotherapeutic agents. patients in 2 arms of the study (Groups B and C) will be given artesunate at 4mg/kg (not exceeding 200mg daily) in combination with imatinib